The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
2022; Elsevier BV; Volume: 191; Linguagem: Inglês
10.1016/j.addr.2022.114614
ISSN1872-8294
AutoresRui Sun, Jiajia Xiang, Quan Zhou, Ying Piao, Jianbin Tang, Shiqun Shao, Zhuxian Zhou, You Han Bae, Youqing Shen,
Tópico(s)Lanthanide and Transition Metal Complexes
ResumoOver the past three decades, the enhanced permeability and retention (EPR) effect has been considered the basis of tumor-targeted drug delivery. Various cancer nanomedicines, including macromolecular drugs, have been designed to utilize this mechanism for preferential extravasation and accumulation in solid tumors. However, such nanomedicines have not yet achieved convincing therapeutic benefits in clinics. Increasing evidence suggests that the EPR effect is over-represented in human tumors, especially in metastatic tumors. This review covers the evolution of the concept, the heterogeneity and limitation of the EPR effect in clinical realities, and prospects for alternative strategies independent of the EPR effect.
Referência(s)